SCL Science Approves Acquisition of SCL Healthcare... "Enhancing Corporate Value"

Digital healthcare specialist SCL Science announced on the 5th that it approved the agenda for a comprehensive stock exchange to make SCL Healthcare a wholly owned subsidiary at an extraordinary general meeting of shareholders.

원본보기 아이콘

SCL Healthcare is a total healthcare specialist company focusing on △clinical trial central lab (C-LAB) business for new drug development △precision medicine-related genetic analysis services △direct-to-consumer (DTC) genetic testing business.

In particular, SCL Healthcare's C-LAB is the first central lab established in Korea in 2006. It currently holds references for over 700 new drug approval clinical trial projects, various specimen analyses, and biomarker validation.

In the genetic analysis business sector, it also received official certification as a DTC genetic testing institution in 2024. Market research firm Global Information forecasts that the DTC genetic testing market will grow at an average annual rate of 16%, reaching $3.32 billion by 2028, raising expectations for business growth.

An SCL Science official stated, “From the second quarter of this year, the results will be consolidated after incorporating it as a subsidiary,” and added, “Considering that SCL Healthcare is a profitable company with sales of 14.6 billion KRW and operating profit of 700 million KRW in 2023, as well as the market growth potential, we are confident it will have a positive impact on SCL Science’s corporate value.”

SCL Science signed a service contract for the development of the C-LAB management system with SCL Healthcare last January. They plan to establish an efficient business process for C-LAB to lay the foundation for the health data platform business.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.